In one paragraphArticle in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
23 authors.
Rui LvShanghai Key Laboratory of Metabolic Remodeling and Health, Institute of Metabolism and Integrative Biology, Fudan University, Shanghai 200437, China.ORCID 0009-0005-0982-385X Leiye YuShanghai Key Laboratory of Metabolic Remodeling and Health, Institute of Metabolism and Integrative Biology, Fudan University, Shanghai 200437, China.ORCID 0000-0001-8698-6787 Jingyi LiuShanghai Xuhui Central Hospital, Zhongshan-Xuhui Hospital, Fudan University, Shanghai 200020, China.ORCID 0000-0003-2180-0210 Youli ZhouKobilka Institute of Innovative Drug Discovery, School of Medicine, The Chinese University of Hong Kong, Shenzhen, Guangdong 518172, China.ORCID 0009-0000-2466-8767 Ruiping HeShanghai Key Laboratory of Metabolic Remodeling and Health, Institute of Metabolism and Integrative Biology, Fudan University, Shanghai 200437, China.ORCID 0009-0003-0454-1912 Chen WangShanghai Key Laboratory of Metabolic Remodeling and Health, Institute of Metabolism and Integrative Biology, Fudan University, Shanghai 200437, China.ORCID 0000-0002-3777-5454 Bing GanShanghai Key Laboratory of Metabolic Remodeling and Health, Institute of Metabolism and Integrative Biology, Fudan University, Shanghai 200437, China.ORCID 0000-0002-2226-3165 Rujuan TiWarshel Institute of Computational Biology, School of Medicine, The Chinese University of Hong Kong, Shenzhen, Guangdong 518172, China.ORCID 0000-0002-5169-8491 Haizhan JiaoKobilka Institute of Innovative Drug Discovery, School of Medicine, The Chinese University of Hong Kong, Shenzhen, Guangdong 518172, China.ORCID 0000-0002-5249-2276 Baohui SongEndoscopy Center and Endoscopy Research Institute, Zhongshan Hospital, Fudan University, Shanghai 200032, China.ORCID 0000-0002-8182-9253 Yiqi ChenShanghai Key Laboratory of Metabolic Remodeling and Health, Institute of Metabolism and Integrative Biology, Fudan University, Shanghai 200437, China.ORCID 0009-0009-3399-1270 Feifei LinChina-Serbia "Belt and Road" Joint Laboratory for Natural Products and Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Zhangjiang Hitech Park, Shanghai 201203, China.ORCID 0009-0007-5292-6146 Mei GaoCentral Research Laboratories, Chongqing Academy of Medical Sciences, Chongqing General Hospital, Chongqing University, Chongqing, China, No.118, Xingguang Avenue, Liangjiang New Area, Chongqing, 401147, China.ORCID 0009-0007-4381-4230 Hongli HuKobilka Institute of Innovative Drug Discovery, School of Medicine, The Chinese University of Hong Kong, Shenzhen, Guangdong 518172, China.ORCID 0000-0003-3658-272X Shankai YinDepartment of Otorhinolaryngology Head and Neck Surgery, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200233, China.ORCID 0000-0003-3689-8599 Pinghong ZhouEndoscopy Center and Endoscopy Research Institute, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Lizhe ZhuWarshel Institute of Computational Biology, School of Medicine, The Chinese University of Hong Kong, Shenzhen, Guangdong 518172, China.ORCID 0000-0001-8252-7807 Mingyan CaiEndoscopy Center and Endoscopy Research Institute, Zhongshan Hospital, Fudan University, Shanghai 200032, China.ORCID 0000-0002-8155-3154 Tian XieMOE Key Laboratory of Geriatric Diseases and Immunology, Biomedical Basic Research Center (BBRC) of Jiangsu, Institute of Molecular Enzymology, School of Life Sciences, Suzhou Medical College of Soochow University, Suzhou, Jiangsu, 215123, China.ORCID 0000-0002-5445-664X Jia LiuChina-Serbia "Belt and Road" Joint Laboratory for Natural Products and Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Zhangjiang Hitech Park, Shanghai 201203, China.ORCID 0000-0002-8167-9750 Li ChenShanghai Key Laboratory of Metabolic Remodeling and Health, Institute of Metabolism and Integrative Biology, Fudan University, Shanghai 200437, China.ORCID 0000-0001-8685-3466 Yunshi ZhongShanghai Xuhui Central Hospital, Zhongshan-Xuhui Hospital, Fudan University, Shanghai 200020, China.ORCID 0000-0002-3128-3168 Ruobing RenShanghai Key Laboratory of Metabolic Remodeling and Health, Institute of Metabolism and Integrative Biology, Fudan University, Shanghai 200437, China.ORCID 0000-0003-4517-7216 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
Remodeling of fatty acid metabolism is increasingly recognized as a critical feature of tumor progression, yet the contribution of very long-chain fatty acid (VLCFA) remains incompletely understood. The elongation of VLCFAs, which is mediated by four consecutive enzymes in the endoplasmic reticulum (ER), has been implicated in tumor progression. However, the molecular mechanisms underlying VLCFA elongation enzymes and their specific contributions to tumorigenesis remain largely elusive. Here, we demonstrate that trans-2-enoyl-CoA reductase (TECR) is upregulated in colorectal cancer (CRC). Structural and biochemical analyses revealed a conserved catalytic mechanism for TECR-mediated trans-2-enoyl-CoA reduction. Moreover, we show that TECR forms a stable complex with 3-hydroxyacyl-CoA dehydratase (HACD), to cooperatively drive VLCFA elongation. A unique U-shaped loop in HACD is critical for recognizing TECR. Disruption of the HACD-TECR interaction interface significantly suppresses CRC cell growth. Collectively, these findings elucidate the molecular mechanism of HACD-TECR-mediated VLCFA elongation and suggest a potential therapeutic strategy for CRC treatment by modulating VLCFA metabolism.
Indexed as
Colorectal NeoplasmsEnoyl-CoA HydrataseFatty AcidsCell Line, TumorHumansProtein BindingEnoyl-CoA HydrataseFatty Acids
Identifiers
PMID42585309
PMCPMC13464631
What OpenQuestion holds
Textmetadata
Read underepoch 390